HSD17B13 and metabolic dysfunction-associated steatohepatitis: A drug targeting HSD17B13, INI-822, has been found to be applicable for fibrotic liver diseases, including non-alcoholic steatohepatitis, and is currently undergoing Phase I clinical trials.